SCHEMBL21552901

SCHEMBL21552901

O=C(O)CCc1cn(-c2ccc(F)cc2)c(=O)c(N2CCCCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 5/20 0.39
TP53 P04637 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
FFAR4 Q5NUL3 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 2/20 0.37
PLA2G4A P47712 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29156973 0.89 LMNA (0.43) NPC1RAB9AALDH1A1TP53HPGD
SCHEMBL21564780 0.86 GABRA2 (0.43) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL21553144 0.85 NPC1 (0.39) NPC1RAB9AALDH1A1TP53KDM4E
SCHEMBL21564604 0.83 NPC1 (0.36) NPC1RAB9AALDH1A1TP53KDM4E
SCHEMBL21553049 0.83 AR (0.37) NPC1RAB9AALDH1A1TP53KDM4E
SCHEMBL21552853 0.77 GABRA2 (0.41) ALDH1A1KDM4EHPGDMAPTMAPK1
SCHEMBL23257964 0.77 AR (0.37) ALDH1A1TP53KDM4EHPGDMAPT
SCHEMBL21553098 0.77 GFER (0.38) ALDH1A1TP53KDM4EHPGDMAPT
SCHEMBL21552943 0.77 KDM4E (0.43) NPC1RAB9ATP53KDM4EHPGD
SCHEMBL21553057 0.76 LMNA (0.38) RAB9AALDH1A1TP53KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
CN-112513020-B KDM1A inhibitors for the treatment of diseases 伊美格生物科学公司 2024-02-23 CN disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
CN-112513020-A KDM1A inhibitors for the treatment of disease 伊美格生物科学公司 2021-03-16 CN disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A NPC1 4463/4885RAB9A 3444/4885ALDH1A1 839/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A NPC1 4463/4885RAB9A 3444/4885ALDH1A1 839/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A NPC1 4422/4885RAB9A 3406/4885ALDH1A1 599/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A NPC1 4463/4885RAB9A 3444/4885ALDH1A1 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.